BackCOSCIENS Biopharma Overview

COSCIENS Biopharma Current Cash

Latest current cash for AEZS: $28M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$27.80M
↓ 34.09% YoYΔ $-14.38M vs prior year quarter

Peer average

Loading

COSCIENS Biopharma Current Cash History

Loading

COSCIENS Biopharma vs. peers: Current Cash Comparison

Loading

COSCIENS Biopharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

COSCIENS Biopharma (AEZS) FAQ

COSCIENS Biopharma (AEZS) currently reports a current cash of $28M as of June 2024. That compares with $42M in the prior-year period — down 34.1% year over year. Use the charts on this page to explore COSCIENS Biopharma's current cash history and peer comparisons.

COSCIENS Biopharma's current cash decreased from $42M to $28M — a 34.1% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

COSCIENS Biopharma reported $28M in current cash as of June 2024. That compares with $42M in the prior-year period — down 34.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $28M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for COSCIENS Biopharma, and consider following AEZS for alerts when major investors trade the stock.

COSCIENS Biopharma is classified in the Healthcare sector. On current cash, it currently shows $28M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AEZS with unrelated industries.